Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMPOWER: Elamipretide in Mitochondrial Myopathy
NCT02367014Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Feb 2015
- Primary completion
- Apr 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elamipretide in mitochondrial myopathy (MM), sponsored by Stealth BioTherapeutics. Started Feb 2015; status: completed.
02
Drugs
elamipretide
03
Conditions
mitochondrial myopathy (MM)
Beyond the preview
Go deeper on NCT02367014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367014.